Citations

Clear

4093 citation(s) found for "Yu, Jonathan".

Neuroimaging and neuropsychological findings in MAPT N279K mutation phenoconverters
Forsberg, Leah K. , Fields, Julie A. , Brushaber, Danielle , Chen, Qin , Gavrilova, Ralitza H. , Graff‐Radford, Jonathan , Graff‐Radford, Neill R., Petersen, Ronald C. , Savica, Rodolfo , Syrjanen, Jeremy A. , Rademakers, Rosa , Kantarci, Kejal , Senjem, Matthew L. , Jack, Clifford R. , Graff‐Radford, Neill R. , Jones, David T. , Knopman, David S. , Kremers, Walter K. , Wszołek, Zbigniew K. , Boeve, Bradley F.

Mayo Clinic

Alzheimer's & Dementia | December 7, 2020 | Volume: 16 | Issue: S6 | Pages: No page available

10.1002/alz.046759 Get It

AbstractBackgroundCharacterization of the changes that occur throughout the transition from asymptomatic to symptomatic for those with familial frontotemporal dementia is essential for planning future disease‐modifying trials.MethodWe identified four related microtubule associated protein tau (MAPT) N279K mutation carriers who have phenoconverted from the asymptomatic to the symptomatic state. Key features were as follows: Case 1 (female) initial exam age 36, onset age 44, current age 49; Case 2 (male) initial exam age 39, onset age 43, current age 48; Case 3 (female) initial exam age 41, onset age 47, current age 53; Case 4 (male) initial exam age 36, onset age 37, current age 46. MRI and neuropsychological data were analyzed.ResultStructural MRI was analyzed using Tensor Based Morphometry Symmetric Diffeomorphic Image Normalization (TBM‐SyN) methodology to quantify lobar volumes, which was then analyzed using a Mixed Effects Model to determine the annual change in lobar volumes. The phenoconverters had a greater estimated annual rate of cortical atrophy in temporal (p <0.001), frontal (p <0.01) and parietal (p <0.05) lobes compared to non‐carriers, with the rate of annual change in symptomatic individuals double that of asymptomatic individuals. Annual change in the parietal and occipital lobes was also analyzed and found to be similar to healthy controls of a similar age. Raw scores on neuropsychological measures were converted to z‐scores for analysis. Category fluency, letter fluency, and Trails A and B were all impaired (z‐score <‐1.5) following phenoconversion, but performance on these and other measures was variable across these four in the late asymptomatic state.ConclusionFor each of the four phenoconverters, structural MRI changes preceded symptom onset, whereas neuropsychological performance was more variable and occurred in closer proximity to the time of phenoconversion. Decrements in verbal fluency and cognitive flexibility were observed earlier than other cognitive domains. These findings suggest that changes in frontal and temporal volume on MRI precede symptom onset, with regional brain volumes most consistently tracking the evolution from the asymptomatic to symptomatic state in N279K MAPT mutation carriers. Supported by: AG063911, AG045390, NS092089, AG016976, AG016574, AG062677.
Neuropsychiatric abnormalities in familial frontotemporal dementia: Findings from the LEFFTDS Cohort
Forsberg, Leah K. , Rosen, Howard J. , Boxer, Adam L. , Syrjanen, Jeremy A. , Brushaber, Danielle , Coppolla, Giovanni, Dickerson, Brad C., Fields, Julie A. , Gavrilova, Ralitza H. , Ghoshal, Nupur , Graff‐Radford, Jonathan, Graff‐Radford, Neill R. , Heuer, Hilary W. , Huey, Edward D. , Karydas, Anna M., Kornak, John , Kramer, Joel H. , Ljubenkov, Peter A. , Mackenzie, Ian R. , McGinnis, Scott, Rademakers, Rosa , Ramos, Eliana Marisa , Rankin, Katherine P. , Rascovsky, Katya, Sturm, Virginia E. , Staffaroni, Adam M. , Taylor, Joanne, Boeve, Bradley F. , Fong, Jamie , Goldman, Jill , Graff‐Radford, Jonathan , Grossman, Murray , Hsiung, Ging‐Yuek Robin , Irwin, David J. , Jones, David T. , Kantarci, Kejal , Knopman, David S. , Kremers, Walter K. , Kukull, Walter A. , Miller, Bruce L. , Wong, Bonnie , Wszołek, Zbigniew K.

Mayo Clinic

Alzheimer's & Dementia | December 7, 2020 | Volume: 16 | Issue: S6 | Pages: No page available

10.1002/alz.045505 Get It

AbstractBackgroundThe LEFFTDS Consortium involves investigators at 8 centers in North America evaluating individuals in kindreds with mutations in microtubule associated protein tau (MAPT), progranulin (GRN), or chromosome 9 open reading frame 72 (C9orf72) genes using a standardized battery of measures. Participants are evaluated annually. We sought to determine possible correlations between FTLD disease progression and neuropsychiatric features.MethodThe Neuropsychiatric Inventory Questionnaire (NPI‐Q) scale is an informant‐based instrument that measures the presence and severity of 12 neuropsychiatric features in patients with dementia. The NPI‐Q was completed at each LEFFTDS visit. The individual NPI questions and total score were analyzed in those with CDR® Dementia Staging Instrument PLUS National Alzheimer Coordinating Center Frontotemporal Lobar Degeneration (CDR®+ NACC FTLD) ratings of 0 (i.e., clinically normal), 0.5 (i.e., questionably/minimally abnormal), 1, 2, and 3.ResultThe 472 participants enrolled to date with a baseline (Visit 1) assessment have the following characteristics: 261 (55.5%) female, mean age 48 (range 18‐80) years, mean education 16 (range 11‐22) years, and 275 participants with a CDR®+NACC FTLD=0 (58%) and known genetic status. Participants with a CDR®+NACC FTLD=0 plus a genetic mutation were compared to those without a mutation and found to have increased severity of apathy (mean score of 0.116 versus 0.035, p=0.0302). Regardless of the specific mutation, those with a CDR®+NACC FTLD=0.5 were reported to have increased severity of apathy, disinhibition, and irritability. For most domains, mean NPI‐Q severity scores increase between groups up to CDR®+NACC FTLD=2. Depression increases in severity up to CDR®+NACC FTLD=1, whereas apathy severity continues to increase with increasing disease severity through CDR®+NACC FTLD=3. Twenty participants converted from CDR®+NACC FTLD 0 to >0 between their baseline and most recent visit; apathy severity almost tripled in these participants. For those that converted, disinhibition, irritability, and NPI total score were different between baseline and most recent visit (Wilcoxon signed rank test, p<0.05).ConclusionKey neuropsychiatric features measured by the NPI‐Q demonstrate differences in apathy severity between clinically normal mutation vs non‐mutation carriers. Key domains differ at different levels of FTLD severity and show dynamic changes with increasing level of FTLD severity. Supported by AG063911, AG045390, NS092089, AG016976.
Studying the natural history of frontotemporal lobar degeneration (FTLD): The ARTFL LEFFTDS longitudinal FTLD (ALLFTD) protocol
Boxer, Adam L. , Rosen, Howard J. , Forsberg, Leah K. , Heuer, Hilary W. , Brushaber, Danielle , Bordelon, Yvette , Dickerson, Brad C., Faber, Kelley , Fagan, Anne M. , Fields, Julie A. , Fishman, Ann, Galasko, Doug, Gavrilova, Ralitza H. , Geschwind, Daniel H. , Ghoshal, Nupur , Graff‐Radford, Jonathan, Graff‐Radford, Neill R. , Grant, Ian , Huey, Edward D. , Karydas, Anna M., Kaufer, Daniel , Kramer, Joel H. , Kornak, John , Lagone, Emma, Ljubenkov, Peter A. , Lucente, Diane , Mackenzie, Ian R. , Manoochehri, Masood , Masdeu, Joseph C. , McGinnis, Scott, Mendez, Mario F. , Miyagawa, Toji , Nelson, Kevin M., Onyike, Chiadi U. , Pantelyat, Alex, Pearlman, Rodney , Petrucelli, Leonard , Rademakers, Rosa , Ramos, Eliana Marisa , Rankin, Katherine P. , Rascovsky, Katya, Ritter, Aaron, Salmon, David P. , Savica, Rodolfo , Staffaroni, Adam M. , Syrjanen, Jeremy A. , Tatton, Nadine , Taylor, Joanne, Weıntraub, Sandra , Wheaton, Diana, Boeve, Bradley F. , Appleby, Brian S. , Biernacka, Joanna M. , Botha, Hugo , Brannelly, Patrick , Dickson, Dennis W. , Domoto‐Reilly, Kimiko , Foroud, Tatiana , Gendron, Tania F. , Goldman, Jill , Graff‐Radford, Jonathan , Grossman, Murray , Hsiung, Ging‐Yuek Robin , Huang, Eric J. , Irwin, David J. , Jones, David T. , Kantarci, Kejal , Knopman, David S. , Kremers, Walter K. , Kukull, Walter A. , Léger, Gabriel C. , Litvan, Irene , Masdeu, Joseph C , Miller, Bruce L. , Pascual, Belén , Rexach, Jessica E. , Roberson, Erik D. , Rojas, Julio C. , Sabbagh, Marwan Noel , Seeley, William W. , Tartaglia, Maria Carmela , Toga, Arthur W. , Wong, Bonnie , Wszołek, Zbigniew K.

Mayo Clinic

Alzheimer's & Dementia | December 7, 2020 | Volume: 16 | Issue: S6 | Pages: No page available

10.1002/alz.045482 Get It

AbstractBackgroundIt is important to determine the natural history of sporadic and familial frontotemporal lobar degeneration (FTLD) and generate clinical, neuropsychological, neuroimaging and biofluid data for planning disease‐modifying trials.MethodAs part of the ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD; U19 AG063911) protocol, investigators at 19 centers in North America will enroll 2100 participants with FTLD over the next 5 years beginning in early 2020.ResultAs of 1/20/20, the ARTFL/LEFFTDS (A/L) Consortium had enrolled 1832 participants, including 850 in kindreds with familial FTLD (239 associated with mutations in MAPT, 192 in GRN, 370 in C9orf72, 4 with mutations in both GRN and C9orf72, and 45 with a mutation in a different gene or no mutation in any known FTLD‐associated gene). Over 500 participants have undergone 2 or more annual visits to date. MRI has been performed in 1105. Biofluid samples have also been collected, with blood (DNA, plasma, serum, mRNA, PBMC) in 1413 and CSF in 303. Over 60 manuscripts using A/L data or samples have been published to date. Five clinical trials involving A/L and ALLFTD participants are in progress or planned. The longitudinal arm in ALLFTD will enroll 500 of existing A/L and 600 future participants for annual assessments with similar methodology to A/L. An additional 1000 FTLD patients will undergo focused one‐time clinical evaluations and biofluid collection.ConclusionThe data/samples from already‐enrolled and planned participants in ALLFTD and findings published to date underscore the utility of evaluating FTLD subjects. The absence of identifiable mutations in some with familial FTLD suggests that other genes are yet to be discovered. ALLFTD data will inform clinical trial design, and many participants will be eligible for future trials. The key data and samples in ALLFTD are available to interested investigators worldwide. Supported by: AG063911, AG045390, NS092089, AG016976, AG21886.
Evolution of the core clinical features of dementia with Lewy bodies
Radford, Jonathan Graff, Wurtz, Lincoln , Aakre, Jeremiah A. , Brushaber, Danielle , Knopman, David S. , Savica, Rodolfo , Graff‐Radford, Neill R. , Drubach, Daniel A., Fields, Julie A. , Pedraza, Otto , Forsberg, Leah K. , Allen, Laura A., Miyagawa, Toji , Silber, Michael H. , Petersen, Ronald C. , Choudhury, Parichita , Jones, David T. , Knopman, David S. , Kantarci, Kejal , Machulda, Mary M. , Louis, Erik K. St. , Kremers, Walter K. , Boeve, Bradley F. , Ferman, Tanis J.

Mayo Clinic

Alzheimer's & Dementia | December 7, 2020 | Volume: 16 | Issue: S6 | Pages: No page available

10.1002/alz.044307 Get It

AbstractBackgroundDementia with Lewy Bodies (DLB) is the second most common cause of degenerative dementia but the evolution of the core clinical features of DLB has not been clearly defined. The objective of this study was to identify the temporal relationship between each core feature from the estimated onset of cognitive symptoms.MethodParticipants include 485 patients with probable DLB who were evaluated at the Mayo Clinic Alzheimer Disease Research Center with neurologic and neurocognitive assessment. Each core clinical feature was compared using Kaplan‐Meier (KM) curves with the sentinel event representing age at which each core feature developed, or time from estimated cognitive onset.ResultThe sample was disproportionately male (76%). Patients were followed longitudinally, with 84% followed until death. Mean MMSE at the last evaluation was 18.3 ± 7.8. KM curves for age of onset and cumulative incidence for DLB core features as time from cognitive onset are provided. REM‐sleep behavior disorder (RBD) developed earliest and in 77% of our sample with a median KM survival estimate of 69 years (95% CI: 67.6–70.8). RBD was present in greater than 50% of patients at cognitive symptom onset. The median KM survival estimate for cognitive symptom onset was 70.2 years (95% CI: 69.3‐71.0). Parkinsonism developed in 89% with a median KM survival estimate of 73.7 years (95% CI: 72.7‐74.7). 76% had fluctuations with a similar median KM survival estimate of 74.6 years (95% CI: 73.7‐75.8). Visual hallucinations (VH) were present in 70% emerging at a median KM survival estimate of 80.2 years (95% CI: 79.5‐ 81.3). Cumulative incidence estimates for median time from cognitive onset to parkinsonism, fluctuations and VH were 2 years (95% CI: 2.0‐2.5), 2.3 years (95% CI: 2.0‐3.2) and 4.3 years (95% CI: 4.0‐4.8 years), respectively.ConclusionIn this DLB cohort, RBD was most likely to precede cognitive onset. The evolution of the other core features after cognitive onset was parkinsonism and fluctuations and then VH. While VH occur about 4 years after cognitive symptom onset, parkinsonism and fluctuations occur within the first 2 years.
Progressive dysexecutive syndrome due to Alzheimer’s disease: A description of 55 cases and comparisons to other clinical AD phenotypes
Townley, Ryan , Graff‐Radford, Jonathan, Przybelski, Scott A. , Reichard, Ross R., Savica, Rodolfo , Drubach, Daniel A., Josephs, Keith A. , Lowe, Val J. , Petersen, Ronald C. , Graff‐Radford, Jonathan , Mantyh, William G. , Botha, Hugo , Polsinelli, Angelina J. , Machulda, Mary M. , Senjem, Matthew L. , Murray, Melissa E. , Boeve, Bradley F. , Knopman, David S. , Jack, Clifford R. , Jones, David T.

Mayo Clinic

Alzheimer's & Dementia | December 7, 2020 | Volume: 16 | Issue: S6 | Pages: No page available

10.1002/alz.040622 Get It

AbstractBackgroundWe report a group of individuals presenting with a progressive dementia syndrome characterized by predominant dysfunction in core executive functions and positive biomarkers for Alzheimer’s pathophysiology.MethodIn this retrospective review, we report on 55 participants with a clinically defined progressive dysexecutive syndrome with 18F‐fluorodeoxyglucose‐positron emission tomography (FDG) and AD biomarker positivity. A subset of these individuals enrolled in our ADRC were compared to other phenotypic variants of AD.ResultSixty‐two percent were female with a mean of 15.2 years of education. Mean age of symptom onset was 53.8 while mean age at diagnosis was 57.2 years. Multi‐domain cognitive impairment was evident in neuropsychological testing with executive dysfunction most consistently and severely affected. The frontal and/or parietal regions demonstrate clear hypometabolism on positron emission tomography in all cases. Genetic testing for autosomal dominant genes was negative in all 8 participants tested and at least one APOE ε4 allele was present in 14/26. EEG was abnormal in 14/17 cases. CSF and neuroimaging biomarkers (PIB‐PET and Tau‐PET) were consistent with Alzheimer’s disease pathophysiology, although CSF p‐tau was normal in 24% of cases. In two participants that came to autopsy, the hippocampus was relatively spared compared to frontal and parietal cortex. Participants presenting with a progressive dysexecutive syndrome and evidence of AD pathology are labeled dAD. Comparing FDG in dAD relative to other AD phenotypes revealed unique areas of relatively greater hypometabolism in parieto‐frontal cortex and relative sparing of medial temporal (vs typical AD), visual (vs PCA), and left temporal (vs lvPPA) (Figure 1). Controlling for age did not alter patterns of regional differences. This demonstrates regional variability related to clinical phenotype not accountable by variation in age, duration, stage, or severity (Figure 2).ConclusionA progressive dysexecutive syndrome should be recognized as a distinct clinical phenotype. This clinical presentation can be due to Alzheimer’s disease but is not specific for any single etiology (non‐AD cases of progressive dysexecutive syndrome will be discussed). Prominent impairment of executive task performance, young‐age of onset, normal CSF p‐tau, and relative preservation of the hippocampus were commonly encountered in this case series of dAD.
White matter hypertensity burden varies in empirically derived incident MCI subtypes
Albertson, Sabrina M., Graff‐Radford, Jonathan , Petersen, Ronald C. , Bondi, Mark W. , Machulda, Mary M. , Lundt, Emily S. , Jack, Clifford R. , Mielke, Michelle M. , Kremers, Walter K. , Knopman, David S. , Jones, David T. , Vemuri, Prashanthi

Mayo Clinic

Alzheimer's & Dementia | December 7, 2020 | Volume: 16 | Issue: S6 | Pages: No page available

10.1002/alz.039560 Get It

AbstractBackgroundWhite matter changes and Alzheimer’s disease pathology frequently co‐exist in the population. Recently we empirically derived subtypes of incident mild cognitive impairment (MCI) and found that there was significant heterogeneity not only in cognitive impairment profiles but also gray matter atrophy suggesting that multiple etiologies may contribute to cognitive impairment in these subtypes. The aim of this study was to examine differences in white matter hyperintensity (WMH) volume in these same MCI subtypes and investigate amyloid deposition in a smaller subset.MethodWe analyzed data from 188 participants with incident MCI enrolled in the population‐based Mayo Clinic Study of Aging (MCSA) identified as having one of four MCI subtypes: subtle cognitive impairment (SCI), amnestic, dysnomic, and dysexecutive. All participants completed 3T imaging at the time of the MCI diagnosis. Using WMH volume scaled by TIV and PIB SUVR, we compared each MCI subtype to 344 cognitively impaired (CU) participants (mean age 78; 46% women) and each other.ResultThe amnestic (n = 83; mean age 80; 43% women), dysnomic (n = 30; mean age 84; 47% women) and dysexecutive subtypes (n = 49; mean age 83; 35% women) had significantly higher WMH volumes compared to CU (p < .02) while the SCI subtype (n = 26; mean age 80; 23% women) did not differ from CU (p = .76). Amongst the MCI subtypes, the amnestic (p = .04) and dysexecutive subtypes (p = .01) had significantly higher WMH volumes than the SCI subtype [Figure 1]. In a smaller subset of individuals who also completed PiB‐PET (17/26 SCI; 39/83 amnestic; 10/30 dysnomic, 28/49 dysexecutive), we found evidence for higher amyloid load in all MCI subgroups except the SCI group (p<0.05) in comparison to CU.ConclusionWe found significantly elevated levels of WMH and amyloid burden in amnestic, dysnomic, and dysexecutive subtypes of incident MCI supporting the notion that both vascular changes and amyloid contribute to the development of clinical symptoms. Surprisingly, WMH and amyloid positivity were not high in SCI suggesting that the pathophysiology in this group needs further investigation.
Functional connectivity is associated with tau spreading in dementia with Lewy bodies
Gunter, Jeffrey L. , Przybelski, Scott A. , Graff‐Radford, Jonathan, Savica, Rodolfo , Lowe, Val J. , Fields, Julie A. , Petersen, Ronald C. , Graff‐Radford, Neill R. , Kantarci, Kejal, Schumacher, Julia , Jones, David T. , Graff‐Radford, Jonathan , Schwarz, Christopher G. , Senjem, Matthew L. , Jack, Clifford R. , Knopman, David S. , Kremers, Walter K. , Ferman, Tanis J. , Boeve, Bradley F. , Thomas, Alan , Taylor, John‐Paul , Kantarci, Kejal

Mayo Clinic

Alzheimer's & Dementia | December 7, 2020 | Volume: 16 | Issue: S2 | Pages: No page available

10.1002/alz.037681 Get It

AbstractBackgroundDementia with Lewy bodies (DLB) is neuropathologically defined by the presence of α‐synuclein aggregations, but many DLB cases show significant Alzheimer’s disease (AD) pathology in the form of β‐amyloid and tau. Our first objective was to investigate the effect of AD co‐pathology on functional network failure in DLB. Secondly, we studied how the distribution of tau relates to functional connectivity in DLB.MethodTwenty‐three DLB, 23 age‐ and sex‐matched AD, and 90 cognitively unimpaired (CU) participants underwent AV1451 tau‐PET, Pittsburgh compound‐B (PiB) PET, and resting state (rs)‐fMRI scans. The rs‐fMRI data were used to calculate the Network Failure Quotient (NFQ), a marker of functional network failure within the default mode network. The NFQ was then correlated with overall cortical tau standardized uptake value ratio (SUVr). The strength of inter‐regional functional connectivity was assessed using the Schaefer100 atlas. Tau‐PET covariance was measured as the correlation in AV1451 SUVr between any two regions across participants. The association between region‐to‐region functional connectivity and tau‐PET covariance was assessed using linear regression. Additionally, we identified the region with highest and the region with lowest tau SUVrs (tau hot‐ and coldspot) and tested whether tau SUVr in all other brain regions was associated with the strength of functional connectivity to these tau hot‐ and coldspots.ResultOverall higher cortical tau‐PET uptake correlated with higher NFQ (i.e. greater functional network failure) in DLB who were PiB+ (N=14, ρ=0.60, p=0.02), but not in DLB who were PiB‐ (N=9, ρ=‐0.06, p=0.87). Higher functional connectivity between regions was associated with higher tau covariance in CU, AD, and DLB, independent of PiB status. Higher functional connectivity of a target region to the tau hotspot (i.e. inferior/medial temporal cortex) was related to higher AV1451 SUVRs in the target region whereas higher functional connectivity to the tau coldspot (i.e. sensory‐motor cortex) was related to lower AV1451 SUVr in the target region.ConclusionGreater tau burden in DLB patients with β‐amyloid co‐pathology is associated with an AD‐like functional network failure. As previously demonstrated within the AD spectrum, functional connectivity may contribute to the spreading of tau across the brain also in DLB.
Economic Evaluation of Catheter Ablation of Atrial Fibrillation in Patients with Heart Failure With Reduced Ejection Fraction
Chew, Derek S. , Loring, Zak , Anand, Jatin , Fudim, Marat , Lowenstern, Angela , Weimer, Kristin E. D. , Atwater, Brett D. , DeVore, Adam D. , Exner, Derek V. , Piccini, Jonathan P. , Rymer, Jennifer A , Noseworthy, Peter A. , Yancy, Clyde W. , Mark, Daniel B.

Mayo Clinic

Circulation: Cardiovascular Quality and Outcomes | December 7, 2020 | Volume: 13 | Issue: 12 | Pages: No page available

10.1161/circoutcomes.120.007094 | PMID 33280436 Get It

Background: Randomized clinical trials have demonstrated that catheter ablation for atrial fibrillation in patients with heart failure with reduced ejection fraction may improve survival and other cardiovascular outcomes. Methods: We constructed a decision-analytic Markov model to estimate the costs and benefits of catheter ablation and medical management in patients with symptomatic heart failure with reduced ejection fraction (left ventricular ejection fraction ≤35%) and atrial fibrillation over a lifetime horizon. Evidence from the published literature informed the model inputs, including clinical effectiveness data from meta-analyses. Probabilistic and deterministic sensitivity analyses were performed. A 3% discount rate was applied to both future costs and benefits. The primary outcome was the incremental cost-effectiveness ratio assessed from the US health care sector perspective. Results: Catheter ablation was associated with 6.47 (95% CI, 5.89–6.93) quality-adjusted life years (QALYs) and a total cost of $105 657 (95% CI, $55 311–$191 934; 2018 US dollars), compared with 5.30 (95% CI, 5.20–5.39) QALYs and $63 040 (95% CI, $37 624–$102 260) for medical management. The incremental cost-effectiveness ratio for catheter ablation compared with medical management was $38 496 (95% CI, $5583–$117 510) per QALY gained. Model inputs with the greatest variation on incremental cost-effectiveness ratio estimates were the cost of ablation and the effect of catheter ablation on mortality reduction. When assuming a more conservative estimate of the treatment effect of catheter ablation on mortality (hazard ratio of 0.86), the estimated incremental cost-effectiveness ratio was $74 403 per QALY gained. At a willingness-to-pay threshold of $100 000 per QALY gained, atrial fibrillation ablation was found to be economically favorable compared with medical management in 95% of simulations. Conclusions: Catheter ablation in patients with heart failure with reduced ejection fraction patients and atrial fibrillation may be considered economically attractive at current benchmarks for societal willingness-to-pay in the United States.
The Military Orthopedics Tracking Injuries and Outcomes Network: A Solution for Improving Musculoskeletal Care in the Military Health System
Mauntel, Timothy C. , Freedman, Brett A. , Provencher, Matthew T. , Tokish, John M. , Lee, Ian E, Bailey, James R. , Burns, Travis C. , Cameron, Kenneth L. , Grenier, Eric, Haley, Chad A., McDonald, Lucas S. , Pallis, Mark, Posner, Matthew, Rivera, Jessica C. , Roach, Christopher J, Robins, Richard J. , Sheean, Andrew J. , Slabaugh, Mark A. , Volk, William R., Dickens, Jonathan F. , Dickens, Jonathan F , Tenan, Matthew S. , Potter, Benjamin Kyle , Provencher, Matthew T. , Rhon, Daniel I. , LeClere, Lance E. , Owens, Brett D. , Roach, Christopher J, Schmitz, Matthew R.

Mayo Clinic

Military Medicine | December 6, 2020 | Volume: 187 | Issue: 3-4 | Pages: e282-e289

10.1093/milmed/usaa304 | PMID 33242087 Get It

Abstract Introduction Musculoskeletal injuries are an endemic amongst U.S. Military Service Members and significantly strain the Department of Defense’s Military Health System. The Military Health System aims to provide Service Members, military retirees, and their families the right care at the right time. The Military Orthopedics Tracking Injuries and Outcomes Network (MOTION) captures the data that can optimize musculoskeletal care within the Military Health System. This report provides MOTION structural framework and highlights how it can be used to optimize musculoskeletal care. Materials and Methods MOTION established an internet-based data capture system, the MOTION Musculoskeletal Data Portal. All adult Military Health System patients who undergo orthopedic surgery are eligible for entry into the database. All data are collected as routine standard of care, with patients and orthopedic surgeons inputting validated global and condition-specific patient reported outcomes and operative case data, respectively. Patients have the option to consent to allow their standard of care data to be utilized within an institutional review board approved observational research study. MOTION data can be merged with other existing data systems (e.g., electronic medical record) to develop a comprehensive dataset of relevant information. In pursuit of enhancing musculoskeletal injury patient outcomes MOTION aims to: (1) identify factors which predict favorable outcomes; (2) develop models which inform the surgeon and military commanders if patients are behind, on, or ahead of schedule for their targeted return-to-duty/activity; and (3) develop predictive models to better inform patients and surgeons of the likelihood of a positive outcome for various treatment options to enhance patient counseling and expectation management. Results This is a protocol article describing the intent and methodology for MOTION; thus, to date, there are no results to report. Conclusions MOTION was established to capture the data that are necessary to improve military medical readiness and optimize medical resource utilization through the systematic evaluation of short- and long-term musculoskeletal injury patient outcomes. The systematic enhancement of musculoskeletal injury care through data analyses aligns with the National Defense Authorization Act (2017) and Defense Health Agency’s Quadruple Aim, which emphasizes optimizing healthcare delivery and Service Member medical readiness. This transformative approach to musculoskeletal care can be applied across disciplines within the Military Health System.
How to conduct cost and value analyses in health professions education: AMEE Guide No. 139
Foo, Jonathan , Cook, David A. , Tolsgaard, Martin G. , Rivers, George , Cleland, Jennifer , Walsh, Kieran , Abdalla, Mohamed Elhassan , You, You , Ilić, Dragan , Levin, Henry M. , Tolsgaard, Martin , Levin, Henry , Maloney, S , Foo, J , Cleland, J , Abdalla, M E , Walsh, K , Ilic, Dragan , You, Michelle You , Golub, Robert , Maloney, Stephen

Mayo Clinic

Medical Teacher | December 5, 2020 | Volume: 43 | Issue: 9 | Pages: 984-998

10.1080/0142159x.2020.1838466 | PMID 33280483 Get It